Scholarlink

<p><i>Pseudomonas aeruginosa</i> is a multidrug-resistant (MDR) pathogen. It causes life-threatening diseases through quorum sensing (QS)–associated virulence. Thus, the attenuation of QS may be an effective strategy to combat the pathogen. In this study, <i>Shewanella indica</i> SU1 isolated from the marine environment showed QS inhibitory activity against biosensor strain <i>Chromobacterium violaceum</i> MTCC 2656. The lead compound was purified and tentatively identified as eicosyl heptafluorobutyrate (EPB). <i>P. aeruginosa</i> MCC 3457 was treated with EPB, and results revealed a reduced production of pyocyanin (79%), rhamnolipids (54%), exopolysaccharide (60%), and biofilm (66%). The motility was greatly affected in EPB-treated cultures. In an in silico approach, EPB exhibited good binding interactions and stability with the target protein LasR. The pharmacokinetics studies divulged that EPB, the lead compound, can be a good drug candidate. This is the first report on the QS inhibitory activity of <i>S. indica</i> SU1 and EPB as an anti-QS compound.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploration of anti-quorum sensing properties of eicosyl heptafluorobutyrate against a clinical strain of Pseudomonas aeruginosa

  • 期刊论文

  • 发表日期：

    2025年7月30日

查看全文
  • Siddhi D. Shah,
  • Saklain Mustak Saiyad,
  • Mirav Patel,
  • Gyan Prakash Rai,
  • Asheesh Shanker,
  • Bhakti Bajpai

摘要

Pseudomonas aeruginosa is a multidrug-resistant (MDR) pathogen. It causes life-threatening diseases through quorum sensing (QS)–associated virulence. Thus, the attenuation of QS may be an effective strategy to combat the pathogen. In this study, Shewanella indica SU1 isolated from the marine environment showed QS inhibitory activity against biosensor strain Chromobacterium violaceum MTCC 2656. The lead compound was purified and tentatively identified as eicosyl heptafluorobutyrate (EPB). P. aeruginosa MCC 3457 was treated with EPB, and results revealed a reduced production of pyocyanin (79%), rhamnolipids (54%), exopolysaccharide (60%), and biofilm (66%). The motility was greatly affected in EPB-treated cultures. In an in silico approach, EPB exhibited good binding interactions and stability with the target protein LasR. The pharmacokinetics studies divulged that EPB, the lead compound, can be a good drug candidate. This is the first report on the QS inhibitory activity of S. indica SU1 and EPB as an anti-QS compound.